WO2011091413A1 - Procédé et forme galénique pour confirmer l'utilisation fidèle au traitement d'un agent bioactif - Google Patents

Procédé et forme galénique pour confirmer l'utilisation fidèle au traitement d'un agent bioactif Download PDF

Info

Publication number
WO2011091413A1
WO2011091413A1 PCT/US2011/022384 US2011022384W WO2011091413A1 WO 2011091413 A1 WO2011091413 A1 WO 2011091413A1 US 2011022384 W US2011022384 W US 2011022384W WO 2011091413 A1 WO2011091413 A1 WO 2011091413A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
substance
dosage form
itself
dose
Prior art date
Application number
PCT/US2011/022384
Other languages
English (en)
Inventor
Richard C. Fuisz
Joseph M. Fuisz
Original Assignee
Fuisz Richard C
Fuisz Joseph M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/692,737 external-priority patent/US20110182827A1/en
Priority claimed from US12/704,742 external-priority patent/US20110182824A1/en
Priority claimed from US12/862,595 external-priority patent/US9943070B1/en
Application filed by Fuisz Richard C, Fuisz Joseph M filed Critical Fuisz Richard C
Publication of WO2011091413A1 publication Critical patent/WO2011091413A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme galénique qui comprend une dose d'au moins un agent bioactif et une substance qui peut être aisément confirmée par le personnel médical pour déterminer si le patient est fidèle à la prise de la forme galénique. La substance est seule ou combinée avec un réactif visible dans la cavité buccale, vaginale, nasale, rectale, auditive, ophtalmique ou stomique d'un patient ou une excrétion d'un patient sous une lumière normale ou par exposition à une source de lumière à une fréquence spéciale.
PCT/US2011/022384 2010-01-25 2011-01-25 Procédé et forme galénique pour confirmer l'utilisation fidèle au traitement d'un agent bioactif WO2011091413A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12/692,737 US20110182827A1 (en) 2010-01-25 2010-01-25 Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent
US12/692,737 2010-01-25
US12/704,742 US20110182824A1 (en) 2010-01-25 2010-02-12 Method and dosage form to confirm compliant use of a bioactive agent
US12/704,742 2010-02-12
US12/862,595 2010-08-24
US12/862,595 US9943070B1 (en) 2010-08-24 2010-08-24 Wireless remotely controlled visual target for training horses

Publications (1)

Publication Number Publication Date
WO2011091413A1 true WO2011091413A1 (fr) 2011-07-28

Family

ID=44307281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/022384 WO2011091413A1 (fr) 2010-01-25 2011-01-25 Procédé et forme galénique pour confirmer l'utilisation fidèle au traitement d'un agent bioactif

Country Status (1)

Country Link
WO (1) WO2011091413A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191805A1 (fr) * 2014-06-11 2015-12-17 Aic Innovations Group, Inc. Système et procédé de surveillance de respect de médication
WO2019180328A1 (fr) * 2018-03-20 2019-09-26 Ab7 Innovation Composition contenant un traceur de substance active ingérée et procédé de détection dudit traceur
US10705073B2 (en) 2014-06-18 2020-07-07 Ruprecht Keller Method for identifying of a biological sample of a mammal, composition for use in this method and kit for performance of this method
US11894119B2 (en) 2019-07-04 2024-02-06 Ruma Gmbh Location-independent ingestion control

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030194374A1 (en) * 2001-01-17 2003-10-16 Xanodyne Pharmacal, Inc. Compositions including a visual marker and method of use thereof
US20040175368A1 (en) * 2001-01-03 2004-09-09 Wisconsin Alumni Research Foundation Use of crystal violet as photochemotherapeutic agent
US7214385B2 (en) * 2001-08-06 2007-05-08 Thomas J. Gruber Pharmaceutical formulation containing dye

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175368A1 (en) * 2001-01-03 2004-09-09 Wisconsin Alumni Research Foundation Use of crystal violet as photochemotherapeutic agent
US20030194374A1 (en) * 2001-01-17 2003-10-16 Xanodyne Pharmacal, Inc. Compositions including a visual marker and method of use thereof
US7214385B2 (en) * 2001-08-06 2007-05-08 Thomas J. Gruber Pharmaceutical formulation containing dye
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191805A1 (fr) * 2014-06-11 2015-12-17 Aic Innovations Group, Inc. Système et procédé de surveillance de respect de médication
US9679113B2 (en) 2014-06-11 2017-06-13 Aic Innovations Group, Inc. Medication adherence monitoring system and method
US9977870B2 (en) 2014-06-11 2018-05-22 Aic Innovations Group, Inc. Medication adherence monitoring system and method
US10475533B2 (en) 2014-06-11 2019-11-12 Aic Innovations Group, Inc. Medication adherence monitoring system and method
US10916339B2 (en) 2014-06-11 2021-02-09 Aic Innovations Group, Inc. Medication adherence monitoring system and method
US11417422B2 (en) 2014-06-11 2022-08-16 Aic Innovations Group, Inc. Medication adherence monitoring system and method
US10705073B2 (en) 2014-06-18 2020-07-07 Ruprecht Keller Method for identifying of a biological sample of a mammal, composition for use in this method and kit for performance of this method
WO2019180328A1 (fr) * 2018-03-20 2019-09-26 Ab7 Innovation Composition contenant un traceur de substance active ingérée et procédé de détection dudit traceur
FR3079303A1 (fr) * 2018-03-20 2019-09-27 Ab7 Innovation Procede pour la detection de la presence d'un traceur dans les excrements
US11894119B2 (en) 2019-07-04 2024-02-06 Ruma Gmbh Location-independent ingestion control

Similar Documents

Publication Publication Date Title
US9125833B2 (en) Multimodal abuse resistant and extended release opioid formulations
CN101511337B (zh) 吸收增强的经粘膜递送装置
AU717711B2 (en) Oral delayed immediate release formulation and method of preparation therefor
ES2463421T3 (es) Formulaciones de fármaco que tienen potencial adictivo reducido
AU2004201228B2 (en) Compositions Including a Visual Marker and Method of Use Thereof
US20120178771A1 (en) Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
US20170079924A1 (en) Compositions and methods for reducing overdose
US20110182807A1 (en) Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent
JP2020536901A (ja) 持続放出医薬製剤及び治療方法
WO2011091413A1 (fr) Procédé et forme galénique pour confirmer l'utilisation fidèle au traitement d'un agent bioactif
CN101677543A (zh) S-腺苷甲硫氨酸的延时释放药物制剂
Kumar et al. Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review
Rana et al. Emerging trends in abuse-deterrent formulations: technological insights and regulatory considerations
JP6544749B2 (ja) 過量服用を減らすための組成物および方法
CN101172105A (zh) 左乙拉西坦在制备益智药物中的用途
US20110182827A1 (en) Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent
WO2016084099A1 (fr) Composition de capsule en gélatine souple d'agents antitussifs
US20110182824A1 (en) Method and dosage form to confirm compliant use of a bioactive agent
US20180147301A1 (en) Solid oral composition containing dyes
Stanko et al. Squamous cell carcinoma and piercing of the tongue–A case report
Mishra et al. Formulation and evaluation of mouth dissolving tablets of carvedilol
Dasgupta Fighting the Opioid Epidemic: The Role of Providers and the Clinical Laboratory in Understanding Who is Vulnerable
JP6371463B2 (ja) 即時放出性乱用抑止性液体充填剤形
Crews et al. Recovery of morphine from a controlled‐release preparation: A source of opioid abuse
JP2003095981A (ja) 医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11735348

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11735348

Country of ref document: EP

Kind code of ref document: A1